IRON PROTEIN SUCCINYLATE PDF

We'd like to understand how you use our websites in order to improve them. Register your interest. This prospective, double-blind, controlled, multicentre trial was carried out to evaluate the efficacy and tolerability of iron protein succinylate ITF in comparison with iron sulfate in the treatment of iron deficiency anaemia. The circulating haemoglobin increased from 9. The differences between the treatments were not statistically significant. A marked clinical improvement in anaemic symptoms paleness, asthenia, tiredness was observed with both treatments.

Author:Malajind Banris
Country:Honduras
Language:English (Spanish)
Genre:Software
Published (Last):13 April 2012
Pages:245
PDF File Size:17.68 Mb
ePub File Size:13.14 Mb
ISBN:963-5-95932-288-4
Downloads:55000
Price:Free* [*Free Regsitration Required]
Uploader:Vigor



A prospective, controlled, double-blind, double-dummy, multicenter clinical trial was made to assess the efficacy and tolerability of iron-protein-succinylate ITF in comparison with a well known iron preparation in the treatment of iron deficiency or iron deficient anemia.

Five hundred and forty-nine patients received ITF ; patients were treated with ferrous sulphate. Both treatments lasted 60 days. The treatment outcome was checked by evaluating special hematology, symptomatology, safety hematology and hematochemistry. After two months of treatment, the normalization of the main hematologic parameters in both groups was detected.

Although in the first month the reference treatment appears to provide somewhat faster results, at the end of the observation, the values of hematocrit, hemoglobin and ferritin were greater in the ITF group, indicating a more progressive and steady therapeutic effect. The overall clinical rating was significantly in favor of ITF , with By dividing the patient population according to pathological conditions iron deficiency or overt anemia , or according to the etiopathogenesis of the iron deficiency increased requirement, or increased loss in adults and in the elderly , separate analyses on the treatment outcome were made and have been included.

The general tolerability, although favorable with both treatments, was significantly more favorable with ITF With this medication, 63 patients These observations confirm that, although the most modern preparations of ferrous sulphate exhibit a relatively low frequency of adverse events of limited clinical concern, it is nevertheless possible to decrease both the prevalence and the duration of such events without prejudice for the clinical efficacy, with the use of more "physiological" preparations in which the iron is reversibly bound to a protein carrier, thus effectively removing one of the main obstacles to the correct compliance with treatments that must be administered for prolonged periods of time.

This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable.

Search: Search. Advanced Clipboard. Create file Cancel. Email citation To:. Format: Summary Summary text Abstract Abstract text.

Send email Cancel. Add to Collections Create a new collection Add to an existing collection. Name your collection: Name must be less than characters. Choose a collection: Unable to load your collection due to an error Please try again.

Add Cancel. Add to My Bibliography My Bibliography. Unable to load your delegates due to an error Please try again. Your saved search Name of saved search:. Search terms:. Test search terms. Would you like email updates of new search results? Email: change. Frequency: Monthly Weekly Daily. Which day? Send at most: 1 item 5 items 10 items 20 items 50 items items items. Send even when there aren't any new results.

Optional text in email:. Save Cancel. Create a file for external citation management software Create file Cancel. Cite Favorites. Abstract A prospective, controlled, double-blind, double-dummy, multicenter clinical trial was made to assess the efficacy and tolerability of iron-protein-succinylate ITF in comparison with a well known iron preparation in the treatment of iron deficiency or iron deficient anemia. Similar articles Controlled, double-blind, multicenter clinical trial of iron protein succinylate in the treatment of iron deficiency in children.

Careddu P, Scotti A. Careddu P, et al. Iron protein succynilate in the treatment of iron deficiency: potential interaction with H2-receptor antagonists. Bianchi FM, et al. PMID: Comparative assessment of the bioavailability, efficacy and safety of a modified-release MR carbonyl iron tablet and oral conventional iron preparation in adult Indian patients with nutritional iron deficiency anaemia.

Adsul BB, et al. J Indian Med Assoc. Chemical and biological characterization of iron-protein succinylate ITF Cremonesi P, Caramazza I. Cremonesi P, et al. PMID: Review. Toblli JE, Brignoli R. Toblli JE, et al. Show more similar articles See all similar articles. Cited by 5 articles Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. Tolkien Z, et al.

PLoS One. Iron status in the elderly. Fairweather-Tait SJ, et al. Mech Ageing Dev. Epub Nov The gut microbiome, kidney disease, and targeted interventions. Ramezani A, Raj DS. Ramezani A, et al.

J Am Soc Nephrol. Pain management in patients with inflammatory bowel disease: insights for the clinician. Srinath AI, et al. Therap Adv Gastroenterol. Overview of clinical trials in the treatment of iron deficiency with iron-acetyl-aspartylated casein. Lazzari F, Carrara M.

Lazzari F, et al. Clin Drug Investig. Publication types Clinical Trial Actions. Comparative Study Actions. Multicenter Study Actions. Randomized Controlled Trial Actions. MeSH terms Adolescent Actions. Adult Actions. Aged Actions. Aged, 80 and over Actions. Delayed-Action Preparations Actions.

Double-Blind Method Actions. Female Actions. Hematologic Tests Actions. Humans Actions. Italy Actions. Male Actions. Metalloproteins Actions. Middle Aged Actions. Prospective Studies Actions. Succinates Actions. Treatment Outcome Actions. Substances Delayed-Action Preparations Actions. Ferrous Compounds Actions. Milk Proteins Actions. Organometallic Compounds Actions. Iron Actions.

CHARLES STROSS HALTING STATE PDF

Iron Protein Succinylate Dosage

Please note that Smart Patients does not conduct clinical trials. If you would like to enroll in a trial or if you need more information please contact the trial team directly. This study aims to evaluate the effect of standard heart failure therapy plus oral solution with protein succinylate iron compared to placebo on the primary end point of 6 minute walk distance at 24th week in patients with chronic ejection fraction reduction heart failure and iron deficiency. Inclusion Criteria: 1. Sign informed consent form; 2. Between 18 to 80 years old, male or female; 3. Patients with chronic ejection fraction reduction heart failure, has been accepted the medication recommended by the Guidelines for treatment of heart failure in China for at least 4 weeks that comply with the following requirements : if there is no contraindications or intolerance, patients should receive the renin angiotensin aldosterone system inhibitors, B blockers, and no dose adjustment within 4 weeks not including diuretics.

SURT2000XLI PDF

Iron protein succinylate Side Effects

A prospective, controlled, double-blind, double-dummy, multicenter clinical trial was made to assess the efficacy and tolerability of iron-protein-succinylate ITF in comparison with a well known iron preparation in the treatment of iron deficiency or iron deficient anemia. Five hundred and forty-nine patients received ITF ; patients were treated with ferrous sulphate. Both treatments lasted 60 days. The treatment outcome was checked by evaluating special hematology, symptomatology, safety hematology and hematochemistry. After two months of treatment, the normalization of the main hematologic parameters in both groups was detected. Although in the first month the reference treatment appears to provide somewhat faster results, at the end of the observation, the values of hematocrit, hemoglobin and ferritin were greater in the ITF group, indicating a more progressive and steady therapeutic effect. The overall clinical rating was significantly in favor of ITF , with

BS EN 998-2 PDF

Study record managers: refer to the Data Element Definitions if submitting registration or results information. This clinical trial was designed as a multicenter, prospective, randomized, double-blind controlled study. Patients were randomly divided into one of two treatment groups:. Talk with your doctor and family members or friends about deciding to join a study.

Related Articles